Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 4/20 | 0.43 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.43 |
| ▸ | PGR | P06401 | 3/20 | 0.40 |
| ▸ | BACE1 | P56817 | 5/20 | 0.39 |
| ▸ | CTSC | P53634 | 2/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12673348 | 0.88 | CYP11B1 (0.44) | CTSCCTSK | |
| SCHEMBL22510544 | 0.83 | HSD17B1 (0.38) | HSD17B1HSD17B2PGRBACE1CTSC | |
| SCHEMBL12673350 | 0.81 | HSD17B1 (0.50) | HSD17B1HSD17B2CTSCCTSKGRIN2B | |
| SCHEMBL12310483 | 0.81 | HSD17B1 (0.43) | HSD17B1HSD17B2PGRBACE1S1PR1 | |
| SCHEMBL9965314 | 0.80 | HSD17B1 (0.45) | HSD17B1HSD17B2PGRBACE1S1PR1 | |
| SCHEMBL12673461 | 0.79 | HSD17B1 (0.40) | HSD17B1HSD17B2PGRBACE1S1PR1 | |
| SCHEMBL16309204 | 0.79 | SLC5A2 (0.42) | HSD17B1HSD17B2PGRBACE1CTSC | |
| SCHEMBL17192152 | 0.77 | SNCA (0.47) | HSD17B1HSD17B2PGRBACE1PIK3CD | |
| SCHEMBL146741 | 0.77 | BACE1 (0.39) | HSD17B1HSD17B2PGRBACE1CTSC | |
| SCHEMBL12310278 | 0.77 | HSD17B1 (0.43) | HSD17B1HSD17B2PGRBACE1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202854-B2 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2012-06-19 | — | — | US | disclosed |
| US-20110280867-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2011-11-17 | — | — | US | disclosed |
| US-8012960-B2 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2011-09-06 | — | — | US | disclosed |
| US-20110160207-A1 | HETEROCYCLIC AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-06-30 | — | — | US | disclosed |
| US-7935696-B2 | e.g. 5-(4-Chlorophenyl)-N-(5-(cyclopropylcarbamoyl)-2-methylphenyl)furan-2-carboxamide; p38 alpha and beta kinase inhibitor; antiinflammatory agent; asthma, inflammatory bowel disease, osteoporosis, psoriasis, graft vs. host rejection, atherosclerosis, multiple myeloma, pain, myocardial ischemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-03 | — | — | US | disclosed |
| US-20100247519-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2010-09-30 | — | — | US | disclosed |
| US-7763606-B2 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070099898-A1 | Heterocyclic aspartyl protease inhibitors | MERCK SHARP & DOHME LLC | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099898-A1 | Heterocyclic aspartyl protease inhibitors | CHRM1, ACHE, CHRM2 | HSD17B1 1173/4885HSD17B2 1671/4885PGR 1504/4885 |
| US-20100247519-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, ACHE, CHRM2 | HSD17B1 1173/4885HSD17B2 1671/4885PGR 1504/4885 |
| US-20110280867-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, ACHE, CHRM2 | HSD17B1 1173/4885HSD17B2 1671/4885PGR 1504/4885 |
| US-20110160207-A1 | HETEROCYCLIC AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | MAP3K1, MAP3K8, MAP3K20 | HSD17B1 1927/4885HSD17B2 2008/4885PGR 1867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.